Creating a new type of anticoagulant from carbohydrates
Development of anticoagulant sulfated glycans
This study is testing a new, safer blood thinner made from synthetic sugars that could replace animal-based options, aiming to help patients avoid risks linked to animal products.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glycan Therapeutics Corporation NIH-funded |
| Lab location | 1 site (Raleigh, UNITED STATES) |
| Project ID | NIH-10907995 on NIH RePORTER |
What this research studies
This research focuses on developing a synthetic carbohydrate-based anticoagulant called sulfated glycan 8-mer to replace animal-derived low-molecular weight heparin (LMWH). The project aims to produce this compound using a novel chemoenzymatic method, which allows for a more consistent and safer alternative to current anticoagulants. The research will involve scaling up the production of the 8-mer and conducting pharmacodynamic analyses in advanced animal models to evaluate its effectiveness compared to existing treatments. Patients can benefit from a safer anticoagulant that reduces the risk of contamination and adverse reactions associated with animal-sourced products.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients requiring anticoagulation therapy, particularly those who may be at risk for complications from traditional heparin treatments.
Not a fit: Patients who do not require anticoagulation therapy or those with contraindications to anticoagulants may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a safer and more effective anticoagulant option that minimizes the risk of contamination and adverse effects.
How similar studies have performed: While the approach of developing synthetic anticoagulants is being explored, this specific method using sulfated glycan 8-mer is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Raleigh, UNITED STATES
- Glycan Therapeutics Corporation — Raleigh, United States (Active)
Researchers
- Principal investigator: Pagadala, Vijayakanth — Glycan Therapeutics Corporation
- Study coordinator: Pagadala, Vijayakanth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.